See more : CN Energy Group. Inc. (CNEY) Income Statement Analysis – Financial Results
Complete financial analysis of The Oncology Institute, Inc. (TOI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Oncology Institute, Inc., a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Spectris plc (SXS.L) Income Statement Analysis – Financial Results
- Homeland Interactive Technology Ltd. (3798.HK) Income Statement Analysis – Financial Results
- Public Joint Stock Company Territorial Generation Company No. 14 (TGKN.ME) Income Statement Analysis – Financial Results
- BSEL Infrastructure Realty Limited (BSELINFRA.NS) Income Statement Analysis – Financial Results
- Maj Invest Kontra (MAJKST.CO) Income Statement Analysis – Financial Results
The Oncology Institute, Inc. (TOI)
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 324.24M | 252.48M | 203.00M | 187.51M | 155.41M | 113.16M |
| Cost of Revenue | 264.67M | 200.39M | 162.16M | 150.64M | 125.46M | 86.88M |
| Gross Profit | 59.57M | 52.09M | 40.85M | 36.88M | 29.94M | 26.28M |
| Gross Profit Ratio | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | 23.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 309.17K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 41.59M | 0.00 | 0.00 |
| SG&A | 113.85M | 119.69M | 83.37M | 41.90M | 29.64M | 20.39M |
| Other Expenses | 22.74M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| Operating Expenses | 136.59M | 124.10M | 86.71M | 45.07M | 32.59M | 21.49M |
| Cost & Expenses | 401.26M | 324.49M | 248.86M | 195.71M | 158.05M | 108.37M |
| Interest Income | 0.00 | 4.08M | 320.00K | 254.15K | 3.38K | 0.00 |
| Interest Expense | 6.78M | 4.08M | 320.00K | 347.06K | 3.38K | 1.59K |
| Depreciation & Amortization | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M | 1.10M |
| EBITDA | -70.45M | 8.40M | -7.94M | -11.29M | 307.11K | 9.08M |
| EBITDA Ratio | -21.73% | -26.57% | -20.43% | -6.02% | 0.20% | 5.27% |
| Operating Income | -77.02M | -72.01M | -45.86M | -8.20M | -2.63M | 4.79M |
| Operating Income Ratio | -23.75% | -28.52% | -22.59% | -4.37% | -1.70% | 4.23% |
| Total Other Income/Expenses | -6.09M | 81.86M | 34.26M | -6.62M | 6.63K | 71.18K |
| Income Before Tax | -83.10M | 1.90M | -11.60M | -14.81M | -2.64M | 4.86M |
| Income Before Tax Ratio | -25.63% | 0.75% | -5.71% | -7.90% | -1.70% | 4.30% |
| Income Tax Expense | -36.00K | 247.00K | -671.00K | -492.82K | 1.38M | 912.75K |
| Net Income | -83.07M | 1.66M | -10.93M | -14.32M | -4.02M | 3.95M |
| Net Income Ratio | -25.62% | 0.66% | -5.38% | -7.64% | -2.59% | 3.49% |
| EPS | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| EPS Diluted | -0.92 | 0.02 | -0.16 | -0.24 | -0.06 | 0.14 |
| Weighted Avg Shares Out | 73.75M | 72.79M | 66.23M | 59.12M | 64.45M | 28.75M |
| Weighted Avg Shares Out (Dil) | 73.75M | 80.61M | 66.23M | 59.12M | 64.45M | 28.75M |
The Oncology Institute Executive Leaders to Present at the 2023 Association for Value-Based Cancer Care (AVBCC) Summit
CERRITOS, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (TOI) is excited to announce that multiple executives including CEO, Dr. Daniel Virnich, CMO, Dr. Yale Podnos, and other senior clinical leaders, will be participating...
The Oncology Institute Regains Compliance with Nasdaq Listing Requirements
CERRITOS, California, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI) (the “Company”), one of the largest value-based community oncology groups in the United States, today announced that it received written notice from the Listing Qualifications Staff of...
The Oncology Institute, Inc. (TOI) Q2 2023 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Taji...
Ambience Healthcare and The Oncology Institute (TOI) Partner to Create a Best-in-Class Oncology Experience for Patients and Clinicians, Leveraging Breakthrough Generative AI Technology
CERRITOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ambience Healthcare, a market leader in generative AI technology for clinical documentation, workflows, and patient experience, and The Oncology Institute (TOI), a premier provider of cutting-edge cancer care, are announcing a landmark...
The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
CERRITOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months...
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the Second Quarter Ended June 30, 2023
TORONTO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or the “Company”) for the second quarter ended June 30, 2023. Please note...
The Oncology Institute Announces Second Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2023 financial results after...
3 Penny Stocks That Have Game-Changing Technologies
The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.
The Oncology Institute Announces First Quarter 2023 Earnings Release Date and Conference Call
CERRITOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2023 financial results after...
Topicus.com has signed a purchase agreement to acquire
TORONTO, March 17, 2023 (GLOBE NEWSWIRE) — Topicus.com Inc. (TSXV: TOI) subsidiary Topicus.com BV has signed a purchase agreement for the acquisition of Five Degrees Holding B.V. (“five°degrees”), pending closing conditions such as merger control approvals, among others. five°degrees was...
Source: https://incomestatements.info
Category: Stock Reports